Media Coverage
As part of our mission of Advancing Cancer Diagnostics and Improving Lives, the team at Leica Biosystems consistently demonstrates thought leadership in the field of pathology with our experts frequently featured in third-party publications. They are at the forefront of innovation and drive conversations on topics like digital pathology, precision medicine, and artificial intelligence.
Here you'll find a curated list of engagements highlighting our commitment to advancing the science and practice of pathology, while sharing insights with the broader scientific and medical community. As you'll see, our experts are widely-regarded as authoritative voices shaping anatomical pathology worldwide.
Dr. Jessica Baumann Shares Insights in Biomarkers Report From Drug Target Review
August 5, 2025
In the Drug Target Review report, Beyond the Lab: Biomarkers Powering Tomorrow’s Therapies, Dr. Jessica Baumann shared her views on how technologies like digital pathology and AI-powered image analysis are enabling greater insight into biomarker behavior across tumor landscapes. As Leica Biosystems’ Medical Director for Companion Diagnostics and Advanced Assays, Dr. Baumann discussed the limitations of traditional biomarker methods and highlighted the promise of computational diagnostics in transforming pathology.
360Dx Recaps ADLM 2025: Leica Biosystems is the Lead Player in Danaher’s Oncology Strategy
July 31, 2025
At ADLM 2025, Leica Biosystems was highlighted as the lead player in Danaher’s oncology strategy, particularly in digital pathology. With a large global installed base of digital slide scanners and integrated systems, Leica Biosystems is central to advancing precision diagnostics for cancer. Danaher executives emphasized Leica Biosystems’ partnerships with pharmaceutical companies—such as an ongoing collaboration with AstraZeneca—to co-develop diagnostics that improve cancer care. As Danaher transitions from siloed subsidiaries to a unified Diagnostics group, Leica Biosystems’ role becomes even more critical in shaping oncology solutions through cross-functional collaboration, innovation, and strategic partnerships.
Multiplexing and Chromogenic Staining Are Especially Valuable as Part of Spatial Profiling According to Traci Degeer
July 29, 2025
Spatial profiling has revolutionized immune research by enabling simultaneous mapping of immune cell location, interactions, and molecular features in tissue biopsies. In an article from Biocompare spotlighting this advancement, Traci DeGeer, Director of Advanced Staining Innovation at Leica Biosystems, emphasized the role of techniques like multiplex immunofluorescence and chromogenic staining. DeGeer explained how these approaches are especially valuable when working with small, precious tissue samples. She also underscored the growing challenge of managing large, complex datasets, as multimodal analyses create resource-intensive bottlenecks.
Karan Arora and Dr. Rob Monroe Share Their Views on Computational Pathology Adoption on BioSpace
July 14, 2025
Karan Arora, SVP , at Leica Biosystems, and Dr. Rob Monroe, Chief Medica l Officer at Leica Biosystems, co-authored an opinion column for BioSpace titled “Tomorrow’s Precision Therapeutics Depend on Precision Diagnostics.” In the article, they discuss the essential role that computational pathology adoption plays in enabling next-generation targeted oncology therapies to reach their full potential. With fewer than 20% of labs currently adopting computational pathology, they emphasize its importance in advancing precision medicine and improving patient outcomes.
Digitization Addresses Workforce and Complexity Challenges: Olga Colgan Writes on Diagnostics World
July 3, 2025
Workforce recruitment challenges and increasing diagnostic complexity are causing organizations to explore new solutions to meet pathology demands. Dr. Olga Colgan shared her thoughts with Diagnostics World about how digitization addresses these factors while simultaneously creating a self-reinforcing flywheel of efficiency and innovation. She also emphasized the role of AI as an assisting tool that can help prioritize slide review and augment pathologist insight, all while maintaining human oversight.
Modern Techniques Chart a New Course in Oncology: Traci DeGeer Speaks to The Scientist
July 3, 2025
Spatial multiomics is revolutionizing cancer research by enabling high-resolution mapping of the tumor microenvironment’s architecture and molecular interactions. In an interview with Traci DeGeer, Director of Advanced Staining Innovation at Leica Biosystems, she discussed how combining protein and gene expression via spatial multiomics deepens our understanding of tumor-stroma interactions, guiding personalized therapies. Techniques involve labeling, imaging, and AI-assisted multiomic analysis to unravel complex cellular behavior. DeGeer highlighted that while AI accelerates data analysis, expert human interpretation remains crucial for hypothesis generation and troubleshooting. Ultimately, integrating AI with spatial multiomics promises transformative advances in cancer diagnosis and treatment personalization.
Traci DeGeer Interview: How Spatial Biology Is Rewriting Our Understanding of Cancer
June 27, 2025
Drug Discovery News spoke with Traci DeGeer, Director of Advanced Staining Innovation at Leica Biosystems, about the role of spatial biology in oncology and how automated workflows are driving broader adoption. In the interview, DeGeer explained how spatial biology is rewriting how we understand cancer, including the complex cellular neighborhoods within tumors. She also shared insights into how automation addresses spatial biology workflow needs for consistency, throughput, and reproducibility by excelling at high-precision repetitive tasks such as staining and imaging. Finally, DeGeer shared her thoughts on the functions that humans are still best suited to fulfill, even as AI becomes more integrated into workflows.
ECDP 2025 Recap by SelectScience: Leica Biosystems Unveils Advanced Digital Pathology Suite
June 25, 2025
In a recap of the European Congress on Digital Pathology (ECDP 2025), SelectScience featured Leica Biosystems’ unveiling of our advanced digital pathology suite—including high-performance scanners and AI-powered software—tailored to support the full translational medicine workflow. This portfolio includes the Aperio GT 180 Digital Pathology Scanner and the flexible Aperio FL Scanning System for whole-slide imaging, as well as Aperio iQC, HALO AP, and HALO Link Software. The recap emphasized the portfolio’s interoperability, smooth integration with laboratory information systems, and third-party tools that can help accelerate cancer research and improve patient outcomes.
Chief Medical Officer Rob Monroe, M.D., Ph.D Interviewed by The Analytical Scientist
April 25, 2025
Dr. Rob Monroe, Chief Medical Officer at Leica Biosystems, was recently interviewed by The Analytical Scientist about precision medicine. He shared his views on the challenges and opportunities in personalized medicine and explained how advanced diagnostic technologies help with patient selection and biomarker targeting. Dr. Monroe also discussed Leica’s commitment to partnering with pharmaceutical companies to develop better companion diagnostics that support precision medicine for all treatments.
Pathology Digitization Editorial by Chief Medical Officer Rob Monroe, M.D., Ph.D Featured by PharmiWeb.com
April 1, 2025
Dr. Rob Monroe, Chief Medical Officer at Leica Biosystems, wrote an editorial, Digitise Pathology to Unlock the Potential of Precision Medicine, which was recently featured by PharmiWeb.com, a leading pharmaceutical media outlet in Europe. In his article, Dr. Monroe discussed ways in which companion diagnostics leverage biomarker analysis to match patients to the most effective treatments and the role of digital pathology in this process. He also shared his predictions for rising demand for these novel diagnostic solutions in the coming decade.
Chief Medical Officer Rob Monroe, M.D., Ph.D Shares Views on Staffing Shortages in Today's Clinical Lab
February 24, 2025
Dr. Rob Monroe, Chief Medical Officer at Leica Biosystems, wrote an editorial discussing the role of computation pathology for offsetting clinical lab staffing challenges in Today's Clinical Lab. In his article, Dr. Monroe shares his perspective on how digital scanners and artificial intelligence can streamline laboratory workflows and provide pathologist with support for key activities.
Karan Arora, SVP, Advanced Assays and Pharma Services Quoted by Scrip Asks
February 21, 2025
Karan Arora, SVP at Leica Biosystems, shared his views on the role of companion diagnostics (CDx) in shaping this year's Biopharma. In the article titled "Scrip Asks... What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances," Karan discussed how the increasing use of transformative companion diagnostics will help ensure that the right medicines are prescribed for the right patients undergoing cancer treatment.
Aperio GT 450 DX Evaluated in Study Published in Archives of Pathology & Laboratory Medicine
February 13, 2025
In a recent, multicenter study published in Archives of Pathology & Laboratory Medicine, the Aperio GT 450 DX Slide Scanner from Leica Biosystems was demonstrated to achieve diagnostic accuracy comparable to conventional light microscopy, whether viewed locally or remotely, with a major-discrepancy rate of just 2.4% (95% CI, 1.4-3.39%). The study was funded by Leica Biosystems and included contributors such as employees, consultants, and advisory board members affiliated with the company. The article also highlighted Leica Biosystems’ critical role as both the provider of the imaging technology under evaluation and as the sponsor of the research.
Read the Full Study at Archives of Pathology & Laboratory Medicine
Karan Arora Discusses Molecular Instruments Partnership with Medical Device Network
January 23, 2025
In an article on Medical Device Network describing Leica Biosystems’ partnership with Molecular Instruments, Karan Arora, SVP of Advanced Assays and Pharma Services, shared his excitement about making innovative technology and automation more accessible and scalable. The partnership, which helps solidify the BOND RX Research Staining System as a leader in research staining automation, enables the simultaneous detection of RNA and protein targets on the same tissue, leading to deeper insights in cancer diagnostics.
LabDesign News Speaks with David Newell and Dr. April Schrank-Hacker
January 13, 2025
David Newell and Dr. April Schrank-Hacker of Leica Biosystems' workflow solutions group spoke with LabDesign News about the adoption of automation in pathology labs. Newell and Schrank-Hacker went into detail about topics such as incorporating lean principles into workflow design, ensuring scalability for the future, lab safety and ergonomics, working within physical constraints, and engaging stakeholders along the way.